The Canadian Patent Office has awarded Streck, Omaha, Neb, a patent regarding its Cell-Free DNA BCT, a direct-draw blood collection tube that stabilizes nucleated blood cells. The patent relates to the use of Streck’s proprietary technology for the collection of samples to analyze fetal nucleic acid.
Connie Ryan, Streck.
“Our unique blood collection tube is widely considered the gold standard for convenient sample collection, transport, and storage of specimens used in cell-free DNA applications by laboratories worldwide,” says Connie Ryan, CEO and president at Streck.
In addition to the Canadian patent, Streck is awaiting imminent issuance of a European patent, and also has several pending US patent applications covering its blood collection tube technology.
The Streck tube prevents the release of genomic DNA, allowing isolation of high-quality cell-free DNA for a wide range of downstream applications commonly used in clinical research studies, drug discovery, and diagnostic assay development. The tube reduces the need for immediate plasma preparation due to its unique stabilization properties. Cell-free DNA is stable for up to 14 days, and circulating tumor cells are stable for up to 7 days at room temperature, allowing convenient sample collection, transport, and storage.
Cell-Free DNA BCT is for research use only, and is not for use in diagnostic procedures in the United States.
For more information, visit Streck.
